# US 12,213,964 B2 · Isoxazoline parasiticide formulations > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,213,964 B2 - Document ID: US12213964B2 - Status: Granted - Kind: B2 - Application number: 18/325,910 - Filed: 2023-05-30 - Published: 2023-09-28 - Granted: 2025-02-04 - Earliest claimed: 2017-12-15 - Assignees: Tarsus Pharmaceuticals, Inc. - Applicants: Tarsus Pharmaceuticals, Inc. - Inventors: Bobak Robert Azamian; Douglas Michael Ackermann; Shawn D. Hickok; Joseph G. Vehige - Web page: https://patentgrep.com/patent/US12213964B2 ## CPC - A61K 31/422: not condensed and containing further heterocyclic rings - A61K 9/0048: {Eye, e.g. artificial tears} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/42: Oxazoles - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61P 27/02: Ophthalmic agents - A61P 33/14: Ectoparasiticides, e.g. scabicides - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed. ## Claims ### Claim 1 An ophthalmic composition comprising: an effective amount of an isoxazoline parasiticide, wherein the isoxazoline parasiticide is present at between about 0.10% and about 0.50% by weight with respect to the total weight of the composition; a hydrogenated castor oil; a polysaccharide thickener; and glycerin, wherein the glycerin is present at between about 0.5% and about 4% by weight with respect to the total weight of the composition. ### Claim 2 (depends on 1) The ophthalmic composition of claim 1, wherein the ophthalmic composition is in eye drop form. ### Claim 3 (depends on 1) The ophthalmic composition of claim 1, wherein the combination of the hydrogenated castor oil and the polysaccharide thickener forms a long-lasting film layer. ### Claim 4 (depends on 1) The ophthalmic composition of claim 1, wherein the ophthalmic composition is characterized by a viscosity, wherein the viscosity is sufficiently high to cause the ophthalmic composition to spread over meibomian gland orifices on upper and/or lower lid margins upon blinking or closing of the eye and to slow evacuation of the ophthalmic composition through the puncta of the eye for at least 20 seconds. ### Claim 5 (depends on 1) The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide comprises lotilaner. ### Claim 6 (depends on 1) The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide is present at about 0.25% by weight with respect to the total weight of the composition. ### Claim 7 (depends on 1) The ophthalmic composition of claim 1, wherein the hydrogenated castor oil comprises polyoxyl 35 castor oil. ### Claim 8 (depends on 1) The ophthalmic composition of claim 1, wherein the hydrogenated castor oil is present at about 5% by weight with respect to the total weight of the composition. ### Claim 9 (depends on 1) The ophthalmic composition of claim 1, wherein the polysaccharide thickener comprises hydroxypropyl methylcellulose. ### Claim 10 (depends on 1) The ophthalmic composition of claim 1, wherein the polysaccharide thickener comprises carboxymethyl cellulose. ### Claim 11 (depends on 1) The ophthalmic composition of claim 1, wherein the polysaccharide thickener is present at between about 0.1% and about 0.5% by weight with respect to the total weight of the composition. ### Claim 12 (depends on 1) The ophthalmic composition of claim 1, wherein the polysaccharide thickener is present at about 0.2% by weight with respect to the total weight of the composition. ### Claim 13 (depends on 1) The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises potassium sorbate. ### Claim 14 (depends on 13) The ophthalmic composition of claim 13, wherein the preservative agent does not comprise lauralkonium chloride or benzalkonium chloride. ### Claim 15 (depends on 1) The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises lauralkonium chloride. ### Claim 16 (depends on 1) The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises benzalkonium chloride. ### Claim 17 (depends on 1) The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent is present at between about 0.15% and about 0.4% by weight with respect to the total weight of the composition. ### Claim 18 (depends on 1) The ophthalmic composition of claim 1, wherein the ophthalmic composition does not comprise tea tree oil. ### Claim 19 (depends on 1) The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide is the sole active ingredient of the ophthalmic composition. ### Claim 20 (depends on 1) The ophthalmic composition of claim 1, wherein the ophthalmic composition is only locally therapeutically effective. ### Claim 21 (depends on 1) The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated as a gel.